You would think we could find a partner who would put up $15 million and fund the phase 3 (another $15-30 million) trial for a 75% cut of B-OM.
That's half what Galera received upfront and infinitely better than self-funding. If we double the share count to fund B-OM you're also indirectly selling half of B-UC and Kevetrin.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links